Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

Fig. 2

Improvement in trough FEV1 at Week 24. Vertical dotted lines indicate quintiles of reversibility at baseline. The MCID is ≥ 100 mL increase of trough FEV1 from baseline [12]. CI, confidence interval; FEV1, forced expiratory volume in 1 s; FP, fractional polynomial; LS, least squares; MCID, minimal clinically important difference; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us